Pompe disease

Maze lands new partner for Pompe drug, after Sanofi pact came apart
BioPharma Dive
Fri, 05/10/24 - 11:29 am
Maze Therapeutics
Pompe disease
Shionogi
FTC
Sanofi
MZE001
Astellas puts the cork back in $350M Xork deal after Cartesian-Selecta merger
Fierce Biotech
Thu, 03/14/24 - 06:22 pm
Astellas
Cartesian Therapeutics
Xork
Pompe disease
Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge
BioSpace
Tue, 12/12/23 - 09:57 am
Ssanofi
Maze Therapeutics
Pompe disease
FTC
legal
FDA approves Amicus Therapeutics' muscle disorder treatment
Reuters
Thu, 09/28/23 - 11:56 am
Amicus Therapeutics
FDA
Pompe disease
AT-GAA
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
BioPharma Dive
Mon, 05/1/23 - 10:10 am
Maze Therapeutics
Pompe disease
Sanofi
MZE001
Astellas Presents Update on Recently Cleared Pompe Gene Therapy Trial
BioSpace
Thu, 02/23/23 - 10:36 am
Astellas
Pompe disease
clinical trials
AT845
Astellas, after years of gene therapy woes, gets rare boost with FDA lifting of Pompe clinical hold
Fierce Biotech
Fri, 01/20/23 - 10:24 am
Astellas
Pompe disease
gene therapy
AT845
FDA again delays review of Amicus rare disease drug
BioPharma Dive
Mon, 10/31/22 - 04:11 pm
Amicus Therapeutics
Pompe disease
China
FDA
AT-GAA
FDA Presses Pause on Astellas' Pompe Disease Therapeutic
BioSpace
Mon, 06/27/22 - 10:07 am
Astellas
Pompe disease
clinical trials
FDA
AT845
FDA hits Amicus with delay on 'breakthrough' Pompe drug
Endpoints
Wed, 05/11/22 - 10:34 am
Amicus Therapeutics
Pompe disease
earnings
AT-GAA
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Fierce Biotech
Mon, 01/10/22 - 11:45 am
Maze Therapeutics
funding
MZE001
Pompe disease
Amicus Splits into Two as FDA Sets PDUFA for Pompe Disease Treatment
BioSpace
Wed, 09/29/21 - 11:56 pm
Amicus Therapeutics
Pompe disease
Caritas Therapeutics
M&A
Sanofi notches another Pompe win with FDA blessing for enzyme replacement therapy Nexviazyme
Fierce Pharma
Sun, 08/8/21 - 12:02 am
Sanofi
Nexviazyme
FDA
Pompe disease
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
EP Vantage
Fri, 07/30/21 - 11:04 am
FDA
Axsome Therapeutics
Sanofi
Merck
Pompe disease
depression
kidney cancer
Keytruda
Sanofi reports sales growth amid Dupixent's China launch, but reveals PDUFA delay in Pompe disease program
Endpoints
Wed, 04/28/21 - 10:30 am
Sanofi
earnings
China
Dupixent
Pompe disease
Amicus Puts Positive Spin on Failure of its Phase III Trial for Pompe Disease
BioSpace
Sat, 02/13/21 - 11:03 pm
Amicus Therapeutics
clinical trials
Pompe disease
AT-GAA
FDA to expedite development of two Sanofi rare disease drugs
Pharmaforum
Thu, 11/19/20 - 10:23 am
Sanofi
FDA
Rare Diseases
Pompe disease
Avalglucosidase alfa
In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan
Endpoints
Fri, 07/17/20 - 11:03 am
Amicus
Pompe disease
clinical trials
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Endpoints
Wed, 06/17/20 - 10:07 pm
Sanofi
Amicus Therapeutics
clinical trials
Pompe disease
Avalglucosidase alfa
Lumizyme
Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth
Endpoints
Mon, 10/8/18 - 10:58 pm
Spark Therapeutics
Pompe disease
SPK-3006

Pages